Zobrazeno 1 - 10
of 99
pro vyhledávání: '"S. J. DeNardo"'
Autor:
M. Klein, M. Lotem, T. Peretz, S. T. Zwas, S. Mizrachi, Y. Liberman, R. Chisin, J. Schachter, I. G. Ron, G. Iosilevsky, J. A. Kennedy, E. Revskaya, A. W. de Kater, E. Banaga, V. Klutzaritz, N. Friedmann, E. Galun, G. L. DeNardo, S. J. DeNardo, A. Casadevall, E. Dadachova, G. B. Thornton
Publikováno v:
Journal of Skin Cancer, Vol 2013 (2013)
There is a need for effective “broad spectrum” therapies for metastatic melanoma which would be suitable for all patients. The objectives of Phase Ia/Ib studies were to evaluate the safety, pharmacokinetics, dosimetry, and antitumor activity of 1
Externí odkaz:
https://doaj.org/article/0a3cb35ec3d64d4695b5567da0be9cfc
Publikováno v:
International journal of oncology. 34(2)
Like rituximab, monoclonal antibodies reactive with human leukocyte antigen have potent antilymphoma activity. However, size limits their vascular and tissue penetration. To mimic monoclonal antibody binding, nanomolecules have been synthesized, show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc39b736c98dd0a177a4b6758e5a295a
https://pubmed.ncbi.nlm.nih.gov/19148487
https://pubmed.ncbi.nlm.nih.gov/19148487
Publikováno v:
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 51(4)
Pretargeted radioimmunotherapy (RIT) is a promising approach to increase the therapeutic index of RIT for malignant solid tumors. For pretargeted RIT of epithelial cancers, such as breast and prostate, mucin 1 (MUC1), the epithelial mucin, was chosen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f72a8a6aeb3d9e50aeca1146547fb8c9
https://pubmed.ncbi.nlm.nih.gov/17464275
https://pubmed.ncbi.nlm.nih.gov/17464275
Publikováno v:
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 48(4)
The United States Food and Drug Administration (FDA) has approved unconjugated monoclonal antibodies (MAbs) for immunotherapy (IT) of B-cell lymphoma, breast cancer and acute myeloid leukemia. More recently, approval has been given for conjugated Zev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5402b834709873015a732abeafb6e1e9
https://pubmed.ncbi.nlm.nih.gov/15640788
https://pubmed.ncbi.nlm.nih.gov/15640788
Publikováno v:
Cancer chemotherapy and biological response modifiers. 19
This promises to be an era of remarkable change for patients afflicted with NHL. Although the cause of NHL remains unknown, there is greater understanding of 'these diseases' at the molecular level. Insights into genetic aberrations that interrupt ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85542b92f1e787474a20b63672c17395
https://pubmed.ncbi.nlm.nih.gov/11686019
https://pubmed.ncbi.nlm.nih.gov/11686019
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 42(9)
Radiometal-labeled monoclonal antibodies are retained longer in tumors than iodinated antibodies, leading to their increased use for radioimmunotherapy. Dissociation of radioiodine from the antibody during metabolism has been documented. We now repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed51aae3c56bcfe22dc31eb8b0d66d56
https://pubmed.ncbi.nlm.nih.gov/11535720
https://pubmed.ncbi.nlm.nih.gov/11535720
Autor:
R T, O'Donnell, S J, DeNardo, A, Yuan, S, Shen, C M, Richman, P N, Lara, I J, Griffith, D S, Goldstein, D L, Kukis, G S, Martinez, G R, Mirick, G L, DeNardo, F J, Meyers
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(6)
Over 31,000 Americans die of androgen-independent metastatic prostate cancer each year. New strategies that do not involve hormonal manipulation but instead recognize the biochemical and molecular characteristics of prostate cancer are needed. Radioi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::09e1858d925ddb63661ad2c2b73ea82a
https://pubmed.ncbi.nlm.nih.gov/11410491
https://pubmed.ncbi.nlm.nih.gov/11410491
Publikováno v:
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 44(3)
Antibody-based constructs genetically engineered from genes of diverse origin provide a remarkable opportunity to develop functional molecular imaging techniques and specific molecular targeted radionuclide therapies. Phage display libraries of antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f5be06ca83566a4235b9b3145037a279
https://pubmed.ncbi.nlm.nih.gov/11105591
https://pubmed.ncbi.nlm.nih.gov/11105591
Publikováno v:
The Prostate. 44(3)
Radioimmunotherapy (RIT) is a new therapeutic modality capable of systemic delivery of radionuclides specifically to sites of metastatic cancer. The L6 monoclonal antibody has been shown to target prostate cancer in preclinical studies and, along wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0ed26841ec0f4bcc00c35e36e852d5c5
https://pubmed.ncbi.nlm.nih.gov/10906734
https://pubmed.ncbi.nlm.nih.gov/10906734
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 13(4)
The use of monoclonal antibodies (MoAbs) for immunotherapy and radioimmunotherapy has ushered in a new era in the treatment of non-Hodgkin's lymphoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b523df25c6af837afcb437bf4f8a66c
https://pubmed.ncbi.nlm.nih.gov/10850358
https://pubmed.ncbi.nlm.nih.gov/10850358